FZD10 is an inclusion criterion in 2 clinical trials for esophageal squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FZD10 status and esophageal squamous cell carcinoma as inclusion criteria, 2 are phase 1 (2 open) [4].

FZD10 is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains FZD10 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) [4].

FZD10 is altered in 0.09% of breast carcinoma patients [3].

FZD10 is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD10 status and breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

FZD10 is an inclusion criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD10 status and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

FZD10 is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD10 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

FZD10 is an inclusion criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD10 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

FZD10 is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD10 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

FZD10 is an inclusion criterion in 1 clinical trial for gastric squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD10 status and gastric squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

FZD10 is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD10 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

FZD10 is an inclusion criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD10 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

FZD10 is altered in 0.01% of malignant solid tumor patients [3].

FZD10 is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FZD10 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [4].

FZD10 is an inclusion criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains FZD10 status and melanoma as inclusion criteria, 1 is phase 1 (1 open) [4].

FZD10 is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD10 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

FZD10 is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD10 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

FZD10 is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD10 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].